C. ROBERT COATES AND MANAGEMENT
INSIGHTS REACH AGREEMENT WITH
NORTHFIELD LABS

DALLAS, Sept. 26 /PRNewswire/ -- C. Robert Coates and Management Insights,  Inc.
announced today that they have reached  agreement with  Northfield  Laboratories
Inc.  on a series of steps  designed  to  promote  increased  understanding  and
investor  awareness  regarding  Northfield and its PolyHeme(TM) blood substitute
product.

Mr. Coates and Northfield's senior management, Richard E. DeWoskin and Steven A.
Gould, met today to discuss ways to enhance the flow of information available to
Northfield's shareholders and others in the scientific,  business and investment
communities.  Northfield indicated that it planned to increase significantly the
resources devoted to investor  relations  activities and to consider  additional
steps to provide  enhanced  information  to its public  investors.  In addition,
Northfield  agreed to explore expanding its board of directors to include one or
more additional independent directors with substantial FDA regulatory experience
or a background in the pharmaceutical industry.

Northfield also provided  clarification that shareholders attending its upcoming
annual  meeting  of  shareholders  would  be  free  to ask  questions  and  make
statements.  Arrangements have been made to permit those shareholders  attending
the annual  meeting in person to view the  business  update  presentation  being
broadcast on the Internet at the meeting site  following  the  conclusion of the
meeting. If the webcast format works well at the annual meeting,  Northfield may
schedule periodic webcasts to update shareholders on the Company's progress.

Mr. Coates and Northfield's senior management agreed to meet periodically in the
future to review the status of the steps being implemented by Northfield.

Following the meeting,  Mr. Coates and Management  Insights  indicated that they
had  determined  to withdraw  their  proposed  slate of  directors  and will not
solicit proxies in connection with the 2000 annual meeting.